Literature DB >> 26948345

Epidemiology.

Kyle M Walsh1, Hiroko Ohgaki2, Margaret R Wrensch3.   

Abstract

More than 250,000 new cases of primary malignant brain tumors are diagnosed annually worldwide, 77% of which are gliomas. A small proportion of gliomas are caused by the inheritance of rare high-penetrance genetic variants or high-dose radiation. Since 2009, inherited genetic variants in 10 regions near eight different genes have been consistently associated with glioma risk via genome-wide association studies. Most of these variants increase glioma risk by 20-40%, but two have higher relative risks. One on chromosome 8 increases risk of IDH-mutated gliomas sixfold and another that affects TP53 function confers a 2.5-fold increased risk of glioma. Functions of some of the other risk variants are known or suspected, but future research will determine functions of other risk loci. Recent progress also has been made in defining subgroups of glioma based on acquired alterations within tumors. Allergy history has been consistently associated with reduced glioma risk, though the mechanisms have not yet been clarified. Future studies will need to be large enough so that environmental and constitutive genetic risk factors can be examined within molecularly defined, etiologically homogeneous subgroups.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  allergy; environment; genetic epidemiology; genome-wide association study; glioma; prognostic marker; risk factors; survival; telomeres; tumor genetics

Mesh:

Substances:

Year:  2016        PMID: 26948345     DOI: 10.1016/B978-0-12-802997-8.00001-3

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  8 in total

Review 1.  Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application.

Authors:  Christos Bikis; Theodora Tzanavari; Krystallenia I Alexandraki; Stamatios Theocharis
Journal:  Horm Cancer       Date:  2018-02-20       Impact factor: 3.869

2.  Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI.

Authors:  Mamta Gupta; Abhinav Gupta; Virendra Yadav; Suhail P Parvaze; Anup Singh; Jitender Saini; Rana Patir; Sandeep Vaishya; Sunita Ahlawat; Rakesh Kumar Gupta
Journal:  Neuroradiology       Date:  2021-01-19       Impact factor: 2.804

3.  The role of informal caregivers for patients with glioma: a systematic review and meta-synthesis of qualitative studies.

Authors:  Dan Chen; Jinfeng Zhu; Qiuning Xu; Fang Wang; Cuiling Ji; Hengdan Di; Ping Yuan; Xiaoyan Bai; Lu Chen
Journal:  Ann Transl Med       Date:  2021-06

4.  Current therapeutic approaches to diffuse grade II and III gliomas.

Authors:  Alberto Picca; Giulia Berzero; Marc Sanson
Journal:  Ther Adv Neurol Disord       Date:  2018-01-17       Impact factor: 6.570

5.  Associations between prediagnostic blood glucose levels, diabetes, and glioma.

Authors:  Judith Schwartzbaum; Michael Edlinger; Victoria Zigmont; Pär Stattin; Grzegorz A Rempala; Gabriele Nagel; Niklas Hammar; Hanno Ulmer; Bernhard Föger; Göran Walldius; Jonas Manjer; Håkan Malmström; Maria Feychting
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

Review 6.  ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas.

Authors:  David Gomez-Zepeda; Méryam Taghi; Jean-Michel Scherrmann; Xavier Decleves; Marie-Claude Menet
Journal:  Pharmaceutics       Date:  2019-12-23       Impact factor: 6.321

7.  The Prognostic Role and Nomogram Establishment of a Novel Prognostic Score Combining with Fibrinogen and Albumin Levels in Patients with WHO Grade II/III Gliomas.

Authors:  Tianshu Jia; Rui Zhang; Fanfei Kong; Qianjiao Zhang; Zhuo Xi
Journal:  Int J Gen Med       Date:  2021-05-28

8.  Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas.

Authors:  Jing Yuan; Xinshuang Yu; Aihua Wang; Yan Li; Fengjun Liu; Yao Wang; Shanmei Sun; Xiuyang Bing; Yiming Liu; Juan Du
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.